Neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus

Clinical Oncology

Volumn 13, Issue 3, 2001, Pages 153-154

  Alderson, D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; MITOMYCIN C;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; EDITORIAL; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; EXPERIENCE; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURGEON; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0034959757     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.9243     Document Type: Editorial

References (5)

1. Combined results from three Phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus
2. Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma
3. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus
4. A prospective longitudinal study examining the quality of life of patients with esophageal cancer